Medyria names Gilles Lachkar, a seasoned bio-pharma and med-tech industry executive, as CEO
Medyria submits its Endovascular Aneurysm Repair First In Man Clinical Study Protocol to BfArM
Medyria finalizes Its Endovascular Aneurysm Repair First In Man Clinical Study Protocol in Collaboration with three prominent university centers in Germany:
- Düsseldorf Univ. - Prof. Dr. med. Hubert Schelzig (Principal Investigator) , Universitätsklinikum Düsseldorf – Klinik für Gefäß- und Endovaskularchirurgie
- Aachen Priv. - Doz. Dr. med. Johannes Kalder, Universitätsklinikum RWTH Aachen – Klinik für Gefäßchirurgie
- Hamburg, Universitätsklinikum UKE, Dr. Kölbel, Dr. Tsilimparis
Medyria raised an additional CHF1.1MM from its initial investors
Medyria is ranked as TOP 100 Swiss startup.
The effort and achievements of Medyria get
recognized with the entering in the
TOP 100 Swiss startup ranking.
Medyria closes series A Financial round of 2.2 MCHF
Successfully performed "first in animal" milestone which triggers second tranche of payment.
Medyria team expands: Gianluca Martena, Biomedical engineer, is now part of the R&D team.
Medyria partner with Investiere for the Series A Financial round.
Medyria gets online on the Investiere web platform raising the interest of several investors.